Key result
MiR483-3p was overexpressed in 68% of adrenocortical carcinomas compared to 12% of adenomas (P<0.05), and its combination with Smad4 improved diagnostic accuracy in borderline cases.
Why the study?
Do clinicopathological criteria and molecular markers (miR483-3p, Smad4) improve diagnostic accuracy in distinguishing adrenocortical carcinomas from adenomas?
Observational (n=65)
Do clinicopathological criteria and molecular markers (miR483-3p, Smad4) improve diagnostic accuracy in distinguishing adrenocortical carcinomas from adenomas?
Absolute Event Rate: 68% vs 12%
p-value: p=<0.05
The combination of miR483-3p and Smad4 expression complements clinicopathological criteria like the Weiss score in distinguishing malignant from benign adrenocortical tumors.
May aid differentiation of borderline adrenocortical tumors when combined with Smad4; leaves open prospective validation before clinical use.
AIMS: To determine clinicopathological criteria and molecular markers helpful in distinguishing adrenocortical carcinomas (ACCs) from adrenocortical adenomas (ACAs). METHODS AND RESULTS: We analysed retrospectively the clinical and pathological features of 50 adrenal cortical tumours, and tested the expression of miR483-3p by in-situ hybridization as well as the expression of IGF2 and Smad4 by immunohistochemistry. We found that tumour size, tumour weight, hormonal function and the Weiss system are all high-efficacy criteria for differentiating malignant from benign tumours (P < 0.001). MiR483-3p was overexpressed in 68% (17 of 25) of ACCs compared to 12% (three of 25) of ACAs (P < 0.05). Using a combination of miR483-3p and Smad4 improved diagnostic accuracy. Molecular markers were then tested in an independent set of 15 borderline tumours. We confirmed that the combined use of miR483-3p and Smad4 immunochemistry can complement the Weiss score in the diagnosis of ACC in cases that display borderline histology. CONCLUSIONS: Tumour size, tumour weight, hormonal function and the Weiss system are useful clinicopathological criteria that can result in accurate diagnosis of most ACCs and ACAs. In challenging cases, miR483-3p and Smad4 expression may help in distinguishing these two entities.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2013) conducted an observational in Adrenocortical carcinomas and adenomas (n=65). miR483-3p and Smad4 expression vs. Adrenocortical adenomas was evaluated on Overexpression of miR483-3p (p=<0.05). MiR483-3p was overexpressed in 68% of adrenocortical carcinomas compared to 12% of adenomas (P<0.05), and its combination with Smad4 improved diagnostic accuracy in borderline cases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: